Neurotrope | Neurotrope Forms Clinical Advisory Board to Support Alzheimer’s Disease Program
22542
post-template-default,single,single-post,postid-22542,single-format-standard,ajax_fade,page_not_loaded,,select-theme-ver-4.4,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Neurotrope Forms Clinical Advisory Board to Support Alzheimer’s Disease Program

 

Newark, NJ, January 13, 2015 — Neurotrope, Inc. (OTCQB: NTRP) today announced the formation of its Alzheimer’s Disease Clinical Advisory Board (CAB) with the following appointments: Jeffery L. Cummings, MD, ScD, CCF, Martin R. Farlow, MD, Sam Gandy, MD, PhD, Christina Sampaio, MD, PhD, and Michael Weiner, MD, among others.

 

Charles S. Ramat, President and Chief Executive Officer of Neurotrope, commented, “We are honored to have these distinguished clinicians and researchers with extensive experience in the field of Alzheimer’s join our Clinical Advisory Board. With our Company having recently completed dosing patients  in our Phase 2a bryostatin study for the treatment of Alzheimer’s disease, the appointment of our CAB members comes at a pivotal time for Neurotrope. We look forward to the release of data from that study early in 2015 and the assistance from our new Clinical Advisory Board members in helping us further the clinical development and eventual commercialization of this important potential treatment for Alzheimer’s disease (“AD”).”

 

“Each of these physicians is a major thought leader in their respective disciplines,” stated Warren W. Wasiewski, MD, Neurotrope’s Executive Vice President of Development and Chief Medical Officer. “Their counsel will be invaluable as they serve as advisors to Neurotrope for our lead drug candidate, bryostatin, which has the potential to make a significant impact not only in Alzheimer’s disease but other neurodegenerative disorders. I look forward to working with the CAB members to help the Company move this promising development program forward.”

 

Abbreviated biographies of our recently appointed CAB members are as follows:

 

Jeffrey L. Cummings, MD, ScD, CCF – Chairman

 

  • Director of Cleveland Clinic Lou Ruvo Center for Brain Health
  • Professor of Neurology and Psychiatry, Director of Materials Science and Engineering Center for AD Research and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA
  • Expert in clinical trial design and analysis, global trial implementation, outcome measures
  • Authored or edited 30 books and published 600 peer-reviewed papers
  • Past President of Behavioral Neurology Society and American Neuropsychiatric Association.

 

Martin R. Farlow, MD

 

  • Professor and Vice Chairman of Research, Dept. of Neurology Indiana University
  • Associate Co-Director of the Indiana AD Center and member of government AD task force
  • Principal Investigator of the Indiana site of the AD Cooperative Study Unit
  • Published 400 peer-reviewed papers.

 

Sam Gandy, MD, PhD

 

  • Mount Sinai Chair in AD Research, Professor of Neurology and Psychiatry at Mount Sinai
  • Director of the Mount Sinai Center for Cognitive Health and NFL Neurological Care
  • Former Chairman of the National Medical and Scientific Advisory Council of the Alzheimer’s Association
  • Founding Director of the Farber Institute of Neurosciences, Jefferson Medical College
  • Discovered PKC regulation of amyloid precursor phosphorylation and processing.

 

Cristina Sampaio, MD, PhD

 

  • Chief Medical Officer at the “Cure Huntington’s Disease Initiative” Foundation
  • Professor of Clinical Pharmacology and Therapeutics University of Lisbon, Portugal
  • Former member of the Committee of Proprietary Medicinal Products and the Scientific Advice Working Party at the European Medicines Agency.

 

Michael Weiner, MD

 

  • Professor UCSF School of Medicine in Radiology and Biomedical Imaging
  • Principal Investigator of the AD Neuroimaging Initiative
  • Educated at Mount Sinai and Yale University, previously Assistant Professor of Medicine at Stanford
  • Established the MR Unit at the San Francisco VA Medical Center.

 

 

 

About Neurotrope

 

Neurotrope Bioscience Inc., the operating subsidiary of Neurotrope, Inc., was formed in October 2012 principally to license, develop and commercialize various novel therapeutic and diagnostic technologies from the Blanchette Rockefeller Neuroscience Institute (BRNI) which are focused on the development of conventional small molecules that are extraordinarily potent in the activation of the enzyme PKCe.  PKCe has been shown to play a central role in the regrowth or repair of nervous tissues, cells or cell products. Neurotrope’s pipeline, under its license from BRNI, includes the drug candidate, bryostatin, for the treatment of Alzheimer’s disease, and a minimally invasive, diagnostic biomarker analysis system which would assess the presence of Alzheimer’s in patients. A Phase 2a study with bryostatin in the treatment of Alzheimer’s disease has completed patient dosing and as previously reported, release of the topline study results is expected early Q1, 2015. In addition, Neurotrope has a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai to utilize its proprietary information and data package for the use of bryostatin-1 in the treatment of Niemann-Pick Type C Disease, a rare disease, mostly of children who are afflicted with Alzheimer-like symptoms. Also, the Company, under its BRNI license, has the rights to develop the licensed technology for other cognitive dysfunctions, including orphan diseases, such as Fragile X Syndrome.

 

Forward-Looking Statements

 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements include statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of commercially viable pharmaceuticals and diagnostics, and (ii) the timing or outcome of the Company’s Phase 2a study with bryostatin in the treatment of Alzheimer’s disease.  Such forward- looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company’s raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and Quarterly Report on Form 10-Q for the fiscal nine months ended September 30, 2014. The Company does not undertake to update these forward-looking statements.

 

Please visit www.neurotropebioscience.com for further information.

 

For additional information, please contact:

Robert Weinstein
Chief Financial Officer
(914) 295-2765
rweinstein@neurotropebioscience.com